Table 1 Characteristics of the trial population at baseline

Age (yr), median (min – max)

43.5 (19–60)

41.5 (20–60)

0.118^*

Sex, no. (%)

 Male

21 (50%)

24 (54.5%)

45

0.837^*

 Female

21 (50%)

20 (45.5%)

41

Blood type, no. (%)

 O

19 (45.2%)

17 (38.6%)

36

0.688^*

 Non-O

23 (54.8%)

27 (61.4%)

50

Body Mass Index (kg/m²), no. (%)

 Underweight

14 (33.3%)

20 (45.5%)

34

0.107^⁋

 Normoweight

21 (50%)

22 (50%)

43

 Overweight/obesity

7 (16.7%)

2 (4.5%)

9

ECOG, no. (%)

 0

26 (61.9%)

29 (52.7%)

55

0.911^⁋

 1

12 (28.6%)

8 (18.2%)

20

 2

4 (9.5%)

7 (15.9%)

11

Khorana score, no. (%)

 Intermediate risk (2)

23 (54.8%)

32 (72.7%)

55

0.131^*

 High risk (≥ 3)

19 (45.2%)

12 (27.3%)

31

Primary site of cancer, no. (%)

 Very high risk of thrombosis

  Pancreas

5 (11.9%)

2 (4.5%)

7

0.109^⁋

  Stomach

2 (4.8%)

1 (2.3%)

3

 High risk of thrombosis

  Lung

8 (19%)

7 (15.9%)

15

  Genitourinary

3 (7.1%)

2 (4.5%)

5

  Gynecology

0 (0%)

2 (4.5%)

2

  Limphoma

4 (9.5%)

5 (11.4%)

9

 Average risk of thrombosis

  Colorectal

14 (33.3%)

17 (38.6%)

31

  Breast

2 (4.8%)

2 (4.5%)

4

  Sarcoma

0 (0%)

2 (4.5%)

2

  Others

4 (9.5%)

4 (9.1%)

8

Stage of cancer at diagnosis, no. (%)

 I

2 (4.8%)

4 (9.1%)

0.962^⁋

 II

5 (11.9%)

5 (11.4%)

 III

13 (31%)

11 (25%)

 IV

22 (52.4%)

24 (54.5%)

Chemotherapy regimen, no. (%)

 5FU Based

20 (47.6%)

20 (45.5%)

0.446^⁋

 Cisplatin Based

14 (33.3%)

14 (31.8%)

 R-CHOP

1 (2.4%)

4 (9.1%)

 BEP

1 (2.4%)

1 (2.3%)

 Taxane Monotherapy

2 (4.8%)

2 (4.6%)

 Anthracycline Based

1 (2.4%)

2 (4.6%)

 ABVD

1 (2.4%)

1 (2.3%)

 GRALL-LYSA

0 (0%)

1 (2.3%)

 De Angelis

0 (0%)

1 (2.3%)

Laboratory parameters

 Haemoglobin (g/dL)

11.05 (7.7–15.3)

11.25 (7.3–15.9)

0.659^⁋

 Leukocyte (× 10³/uL)

13 (4.9–37)

11.9 (5.1–21.8)

0.169^⁋

 Platelet (× 10³/uL)

445 (194–707)

465 (238–951)

0.883^⁋